<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Interpeduncular Nucleus (IPN) Neurons</th>
</tr>
<tr>
<td class="label">Interaction Partner</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">[Medial habenula](/cell-types/medial-habenula)</td>
<td>Primary input</td>
</tr>
<tr>
<td class="label">[Lateral habenula](/cell-types/lateral-habenula)</td>
<td>Negative reward signals</td>
</tr>
<tr>
<td class="label">[Ventral tegmental area](/cell-types/ventral-tegmental-area-dopamine)</td>
<td>Mood and reward</td>
</tr>
<tr>
<td class="label">[Raphe nuclei](/cell-types/dorsal-raphe)</td>
<td>Serotonergic modulation</td>
</tr>
<tr>
<td class="label">[Hippocampus](/cell-types/hippocampal-neurons)</td>
<td>Memory circuits</td>
</tr>
</table>
The interpeduncular nucleus (IPN) is a midbrain structure located in the interpeduncular fossa between the cerebral peduncles. It serves as the primary target of habenular efferents via the fasciculus retroflexus, forming a critical node in the dorsal diencephalic conduction system that connects the forebrain to brainstem structures. The IPN receives dense GABAergic input from the [medial habenula](/brain-regions/habenula) and projects to various downstream targets including the [ventral tegmental area](/brain-regions/ventral-tegmental-area), [raphe nuclei](/brain-regions/raphe-nuclei), and [locus coeruleus](/brain-regions/locus-coeruleus). The IPN plays critical roles in mood regulation, reward processing, nicotine addiction, sleep-wake cycles, and pain modulation. IPN dysfunction has been implicated in [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), depression, and anxiety disorders. The IPN contains morphologically and neurochemically distinct neuronal populations including GABAergic projection neurons, calretinin-expressing neurons, and substance P-containing neurons["@klepper2023"].
The IPN contains multiple subnuclei with distinct connectivity:
GABAergic Projection Neurons: The majority of IPN neurons are GABAergic and project to downstream targets. These neurons express GAD67 (GAD1) and vesicular GABA transporter (VGAT). They provide inhibitory input to VTA dopamine neurons and other targets.
Calretinin-Expressing Neurons: A subpopulation of IPN neurons expresses calretinin (CALB2), a calcium-binding protein. These neurons have distinct electrophysiological properties and may preferentially project to specific downstream targets.
Substance P Neurons: Some IPN neurons contain substance P (TAC1), a neuropeptide involved in pain processing and mood regulation. These neurons receive input from the medial habenula and contribute to stress responses.
Cholinergic Neurons: The IPN contains a smaller population of cholinergic neurons expressing choline acetyltransferase (ChAT). These neurons are involved in reward processing and may contribute to nicotine effects.
Astrocytes: IPN astrocytes regulate extracellular neurotransmitter levels, particularly glutamate and GABA. They express glutamate transporters (EAAT1/GLAST, EAAT2/GLT-1) that prevent excitotoxicity.
Microglia: IPN microglia monitor local environment and respond to pathological changes. Microglial activation has been documented in PD models with altered IPN function.
Medial Habenula: The primary input to IPN comes from GABAergic neurons in the medial habenula (MHb). This input is the largest afferent projection and carries information about aversion, reward prediction error, and nicotine signals.
Lateral Habenula: While primarily targeting VTA and RMTg, lateral habenula also provides indirect input to IPN through MHb interneurons.
Septal Nuclei: Septal inputs provide cholinergic and GABAergic modulation to IPN, influencing mood and memory circuits.
Ventral Tegmental Area (VTA): IPN GABAergic projections to VTA directly inhibit dopamine neurons, modulating reward processing and motivation. This connection is critical for aversion signaling and withdrawal states.
Raphe Nuclei: IPN projects to dorsal and median raphe nuclei, influencing serotonergic tone and mood. This pathway is relevant to depression and anxiety in neurodegeneration.
Locus Coeruleus: Noradrenergic projections from IPN modulate arousal and attention. IPN dysfunction may contribute to sleep-wake disturbances in PD and AD.
Rostral Interpeduncular Nucleus: Subpopulations project to the interpeduncular fossa and surrounding structures.
IPN alterations in AD include:
Tau Pathology: The IPN shows early tau accumulation in AD models and human tissue. As part of the limbic system, IPN may be vulnerable to early pathological changes.
Cholinergic Dysfunction: The IPN contains cholinergic neurons that are affected in AD. Loss of IPN cholinergic signaling may contribute to cognitive deficits.
Mood Symptoms: Depression and anxiety are common in AD. IPN dysfunction through habenular pathways may contribute to these symptoms.
Circuit Hyperexcitability: IPN GABAergic output may be reduced in AD, contributing to circuit hyperexcitability and seizures in some patients.
IPN involvement in PD is increasingly recognized:
L-DOPA-Induced Dyskinesia: IPN activity is altered in models of L-DOPA-induced dyskinesia (LID). The habenula-IPN-VTA pathway may contribute to the maladaptive plasticity underlying LID. Inhibiting IPN output reduces LID severity in animal models[@hattan2022].
Depression and Anxiety: PD patients frequently experience depression and anxiety. IPN dysfunction, particularly through habenula-IPN-raphe pathways, may contribute to these mood symptoms.
Sleep Disorders: IPN orexin interactions modulate sleep-wake cycles. PD patients show altered orexin signaling and IPN-related sleep disturbances.
Olfactory Dysfunction: The IPN receives indirect input from olfactory bulb circuits through the habenula, potentially contributing to anosmia in early PD.
Nicotine Addiction: IPN is a critical node in nicotine addiction. The MHb-IPN-VTA pathway mediates nicotine aversion and withdrawal. This is relevant to smoking in neurodegenerative patients.
Anxiety Disorders: IPN hyperactivity contributes to anxiety-like behaviors. IPN may be a therapeutic target for anxiety in neurodegeneration.
GABA Signaling: IPN neurons use GABA as their primary neurotransmitter. GABA_A receptor activation hyperpolarizes downstream targets. Altered GABA signaling contributes to circuit dysfunction in PD and AD.
Substance P/Tachykinin: Substance P signaling through NK1 receptors modulates pain and mood. Substance P antagonists have been explored as anxiolytics.
Cholinergic Signaling: IPN cholinergic neurons project to VTA and modulate dopamine release. Cholinergic dysfunction contributes to cognitive deficits.
mTOR Pathway: mTOR signaling in IPN regulates synaptic plasticity. Dysregulated mTOR signaling has been implicated in AD and may affect IPN function.
cAMP/PKA: cAMP signaling modulates IPN neuronal excitability. Altered cAMP dynamics contribute to mood symptoms in PD.